Following DNA damage that results in stalled replication fork, activation of ATR-CHK1 signaling induces the DNA damage response (DDR) in transformed cells. In the present studies on human cervical and breast cancer cells, we determined the effects of heat shock protein (hsp) 90 inhibition on the levels and accumulation of DNA damage/repair associated proteins following exposure to γ-ionizing radiation (IR) (4 Gray). We demonstrate that hsp90 inhibition with 17-AAG (17-allylamino-demehoxy geldanamycin) or the novel, non-geldanamycin analogue AUY922 (resorcinylic isoxazole amide, Novartis Pharma) dose-dependently reduced the levels of ATR and CHK1 without affecting ATM levels. AUY922-mediated depletion of ATR and CHK1 was associated with an increase in their 
INTRODUCTION
DNA damage caused by environmental mutagens or reactive metabolic byproducts induces DNA damage response (DDR), which regulates cell cycle transit, DNA repair and apoptosis (1) (2) (3) . DDR involves the phosphorylation and activation of two members of the PIKK (phosphoinositide 3-kinase related kinases) family of protein kinases, Ataxia Telangiectasia Mutated (ATM) and ATM and RAD3-related (ATR) proteins (3, 4) . ATM is activated in response to the uncommon event of DSBs (doublestrand breaks), whereas ATR is activated in response to many different types of DNA damage, including single-strand breaks (SSBs), base adducts, crosslinks and stalled replication forks (3, 4) . ATR is activated when stalled replication forks result during replication of damaged DNA due to bulky adducts, 4 factors and other cytosolic or nuclear proteins (also known as hsp90 client proteins) into their functionally mature and active conformation (17, 18) . ATP binding to the hydrophobic N-terminus pocket also alters hsp90 conformation, promoting the interaction of hsp90 with a set of co-chaperones, which enables the folding of the metastable client proteins into their active conformation (17, 18) .
Previous reports have identified several DDR proteins, including CHK1, DNA-PK, FANCA and BRCA2, as hsp90 client proteins such that hsp90 inhibition attenuates their levels and/or function (19) (20) (21) (22) (23) . Among the reported hsp90 antagonists that are currently being investigated in clinical trials in various human malignancies are the geldanamycin and its analogue 17-AAG, as well as the nongeldanamycin analogue AUY922 (17, 18, (24) (25) (26) . These hsp90 antagonists bind to the N-terminus ATPbinding pocket of hsp90, replacing the nucleotide and inhibiting the chaperone function of hsp90 (17, 18, (24) (25) (26) . For example, binding of AUY922 to hsp90 shifts it from a refolding chaperone complex to the one that promotes degradation of client proteins (24) (25) (26) . The misfolded client proteins are then directed to a covalent linkage with polyubiquitin by an E3 ubiquitin ligase, and subsequently degraded by the 26S proteasome (17, 18, (24) (25) (26) . Therefore hsp90 inhibitors can destabilize and deplete the client proteins involved in DDR, thereby inhibiting DNA repair and increasing the amount of damaged DNA, following treatment of transformed cells with IR, UV or hyperoxia (20, 27, 28) . Consistent with this, treatment with hsp90 inhibitor, e.g., 17-AAG or AUY922, was demonstrated to increase IR-induced gamma H2AX (γH2AX) foci, a marker of DNA double-strand breaks, inhibit the repair of damaged DNA, as well as sensitize transformed cells to IR (20, 27, 28) . In the present studies, we show for the first time that in transformed cells ATR is a bonafide hsp90 client protein. We also demonstrate that treatment with hsp90 inhibitor attenuates the levels of both ATR and CHK1, as well as by inhibiting ATR-CHK1 mediated DDR signaling hsp90 inhibitor treatment increases IR-mediated DNA damage and apoptosis of transformed cells. Louis, MO). Anti-phospho-ATR (S428) and anti-ATM antibodies were purchased from Cell Signaling Technology (Berverly, MA). Anti-CHK1, anti-phospho-CHK1 (S345) and anti-ubiquitin antibodies were purchased from Abcam (Cambridge, MA). Anti-53BP1 antibody was purchased from Novus Biologicals (Littleton, CO) and anti-ATR antibody was obtained from GeneTex (Irvine, CA). Antihsp90 and anti-hsp70 antibodies were purchased from StressGen Biotechnologies (Victoria, BC) and anti-γ-H2AX antibody was obtained from Millipore (Billerica, MA). Anti-β-actin antibody was purchased from Sigma-Aldrich (St. Louis, MO).
DNA damage induction
HeLa and MCF-7 cells were irradiated by γ-ionizing radiation (IR) using a 137 Cs source (Gamma cell 40 extractor, Nordion, Ottawa, ON, Canada) or by microirradiation using LSM510 META confocal microscope (Carl Zeiss, Heidelberg, Germany) equipped with a pulsed Ti:Sapphire laser (800 nm, Mira 900, Coherent Inc., Santa Clara, CA), as previously described (31) . For the induction of replication stress, HeLa cells were treated with 10 mM of hydroxyurea (Sigma-Aldrich, St. Louis, MO) for 2 hours.
Then, cells were harvested or fixed for Western blot analyses or immunofluorescence staining for ATR, p-ATR, ATM, Chk1, 53BP1 and γ-H2AX.
RNA interference and transfection
For short hairpin RNA (shRNA)-mediated down-regulation of ATR, HeLa cells were transiently transfected as per the manufacturer's instructions using lipofectamine 2000 (Invitrogen, Carlsbad, CA) with the plasmid vectors expressing shRNA targeting human ATR or nonspecific control (Santa Cruz Biotechnology, Santa Cruz, CA), as previously described (30, 32) . The cells were washed with media and incubated an additional 24 hours. Forty eight hours after treatment with the vector or ATR shRNA, cells were treated with AUY922 or IR for Western blot or cell cycle analyses.
Flow cytometric analysis
The flow cytometric evaluation of cell cycle status and the percentage of cells in the G 1 , S, and G 2 -M phases were performed according to a previously described method (33) . Briefly, after drug treatment, cells were exposed to 4 Gy of IR and incubated for 8-16 hours at 37°C. Following this, cell cycle status was determined utilizing an Accuri CFlow6 flow cytometer (Accuri, Ann Arbor, MI). For staining with phospho (p)-histone H3 (Ser10) or γ-H2AX, cells were treated with 0.5% BSA for 10 minutes and incubated for 1 hour with Alexa 488-conjugated anti-phospho-histone H3 (Ser10) (Cell Signaling Technology, Berverly, MA) or 6 hours with Alexa 488-conjugated anti-γ-H2AX Cell Signaling Technology, Berverly, MA). Cells were washed with PBS, then stained with To-Pro3 iodide and analyzed by flow cytometry.
Clonogenic cell survival assays
Cells were treated with AUY922 for 16 hours followed by IR. After treatment, 300 cells from each were plated in triplicate and incubated at 37°C with 5% CO 2 for 10 days. At end of the incubation, colonies consisting of 50 or more cells in each well were counted and the surviving fraction was calculated as:
(mean number of colonies)/(number of cells seeded x plating efficiency). Plating efficiency was defined as the mean number of colonies divided by the number of cells seeded for unirradiated control cells (34) .
Western blot analyses and immunoprecipitation
Western blot analyses were performed on protein in the total cell lysates, as previously described (30, 35) . For immunoprecipitation (IP), total cell lysates were mixed with anti-hsp90, anti-ATR or antihsp70 antibody, and incubated overnight at 4°C with rotation. Protein G-agarose beads were added to the antibody/lysate mix and incubated for 3 hours. The beads were washed in lysis buffer (20 mM Tris-7 performed for ATR and CHK1 utilizing a StepOnePlus Real-Time PCR system (Applied Biosystems, Carlsbad, CA) and Power SYBR Green PCR Master Mix (Applied Biosystems, Carlsbad, CA), as previously described (30, 32) . The PCR reactions were cycled 40 times after initial denaturation (95°C, 5 min) with the following parameters: denaturation at 95°C for 15s; annealing at 60°C for 1min.
Expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used to normalize relative expression of the mRNA.
Immunofluorescence staining and confocal microscopy
HeLa and MCF-7 cells were grown on glass coverslides overnight at 37°C. Then cells were treated with AUY922 or IR to induce DNA damage and fixed with 4% paraformaldehyde and 0.5% Triton X-100 for 10 minutes. Following this, the slides were blocked with 3% BSA for 30 minutes and incubated with anti-p-ATR, anti-γH2AX, anti-ATR, anti-ubiquitin, anti-53BP1, anti-ATM or anti-CHK1 antibody for 2 hours at 37°C. The slides were washed three times in 1X PBS and incubated with Alexa Fluor 594 or Alexa Fluor 488-conjugated secondary antibodies for 1 hour. After three washes with 1X PBS, the cells were counterstained using SlowFade Gold antifade reagent with DAPI (Invitrogen, Carlsbad, CA) and imaged using a Zeiss LSM510 confocal microscope with a 63x 1.2 NA objective (Carl Zeiss, Heidelberg, Germany), as previously described (30, 32) .
Analysis of DNA damage repair by comet assay
These studies were performed, as previously described (20) . Briefly, after treatment of AUY922 and IR, cells were harvested, mixed with low-melting agarose and immediately poured onto glass slides. Slides were placed at 4°C in the dark for 10 min and immersed in pre-chilled lysis solution (Trevigen, 
Statistical analyses
Data are expressed as mean plus or minus standard error of the mean (SEM). Comparisons used Student t test. P values less than .05 were assigned significance. Figure 1) . It is noteworthy that 24 to 48 hours following a wash-out of the drug after AUY922 treatment of HeLa cells (100 nM for 16 hours), the levels of ATR, p-ATR and CHK1 were completely restored ( Figure 2C ). This suggests that in cells surviving after the AUY922 treatment, DDR response would also be restored due to repletion of the levels of p-ATR, ATR and CHK1. We next determined the effect of AUY922 and/or IR on the mRNA levels of ATR and CHK1. As shown in Figure 3A , neither AUY922 nor IR treatment significantly affected the mRNA levels of ATR and CHK1 in HeLa cells.
RESULTS

Treatment
Treatment with AUY922 inhibits the activation of ATR and CHK1 and increases γ-H2AX
expression levels following IR. Treatment with an hsp90 inhibitor is known to result in the depletion of the half-life of hsp90 client proteins (32) . Therefore, we determined the effect of AUY922 on the halflife of ATR and CHK1 in HeLa cells, by determining the effect on their expression levels over 16 hours of treatment with 100 μg/ml the protein synthesis inhibitor cycloheximide (CHX) alone versus cotreatment with CHX and AUY922 ( Figure 3B ). As shown, treatment with CHX alone reduced the % fractions remaining over 16 hours of both ATR and CHK1 proteins, which were further attenuated over 16 hours following co-treatment with AUY922 and CHX. This indicated that hsp90 promotes the stabilities of ATR and CHK1 proteins, and AUY922 treatment significantly decreased the half-life of ATR and CHK1. We next studied the effects of hsp90 inhibition on the phosphorylation and activation of ATR and CHK1 in response to DNA damage. Figure 3C shows that exposure to IR alone rapidly induced the levels of p-ATR and p-CHK1 over 16 Treatment with AUY922 inhibits localization of p-ATR, ATR, CHK1 and 53BP1 to sites of DNA damage. We next assessed the effect of AUY922 on the localization of ATR and other DDR proteins involved in DNA damage response and repair to sites of DNA damage. HeLa cells were treated with 100 nM AUY922 for 16 hours followed by exposure to 800 nm laser irradiation known to induce DNA double strand breaks. As shown in Figure 5A and 5B, following laser irradiation ATR and p-ATR accumulated at the sites of laser-induced DNA damage and co-localized with γ-H2AX. However, the accumulation of ATR and p-ATR, and co-localization with γ-H2AX, was inhibited by treatment with AUY922 ( Figure 5A and 5B). Previous reports have highlighted the role of p53BP1 in DNA-damage checkpoint signals and in the recruitment of repair and signaling proteins to the sites of DNA damage following exposure to IR (4, 36) . Consistent with this, we also observed the accumulation of ATR, p53BP1 and γ-H2AX at sites of DNA damage ( Figure 5A ). AUY922 treatment inhibited the localization of p53BP1 and its co-localization with ATR at the sites of DNA damage ( Figure 5A ). In contrast, AUY922 treatment increased γ-H2AX accumulation at the DNA damage sites. However, compared to the untreated control cells, AUY922 treatment attenuated the levels and co-localization of p-ATR with γ-H2AX ( Figure 5B ). Similarly, AUY922 treatment significantly inhibited CHK1 accumulation and colocalization with γ-H2AX at the sites of laser-induced DNA damage ( Figure 5C ). These studies also demonstrated that, as compared to ATR, ATM accumulated at a rate faster than ATR at the sites of laser-induced DNA damage, but AUY922 treatment did not inhibit ATM accumulation ( Figure 5D ).
Depletion of ATR by shRNA enhances sensitivity of cancer cells to IR, but not to AUY922. Next, we determined whether genetic knockdown of ATR would have a similar effect as AUY922 treatment on p-CHK1, γ-H2AX, cell cycle, apoptosis and clonogenic survival. Figure 6A demonstrates that shRNA mediated knockdown of ATR depleted the levels of ATR, p-ATR and p-CHK1, but increased γ-H2AX levels in HeLa cells. ATR knockdown also attenuated IR-mediated increase in p-ATR and p-CHK1 but augmented IR-induced γ-H2AX levels in HeLa cells ( Figure 6A ). ATR knockdown did not affect the total levels of either CHK1 or hsp90 ( Figure 6A ). As demonstrated in Figure 6B Figure 6D ). These results demonstrate that similar to the depletion of ATR by AUY922, ATR knockdown by shRNA also increases IR-mediated growth inhibition and apoptosis in cancer cells.
Treatment with AUY922 depletes ATR and CHK1 in non-proliferating cells. We next determined
whether AUY922-mediated depletion of ATR and CHK1 is due to its effects on cell cycle status. MCF-7 cells were cultured in serum-depleted media (0.5% FBS) for 24 to 72 hours to induce growth arrest and the effects on ATR and CHK1 expression levels were determined. As shown in Figure 7A , MCF-7 cells were arrested in G0/G1 phase after serum starvation. Figure 7B demonstrates that serum starvation induced G0/G1 arrest and resulted in only a modest decline in the levels of ATR and CHK1. Similar modest effect of serum starvation was also seen on DNA-PKcs and mTOR levels. Further, treatment with AUY922 induced significant decline in ATR and CHK1 levels, while inducing only a modest decline in the levels of DNA-PKcs and mTOR ( Figure 7B ). During exposure of MCF7 cells to AUY922, no further changes in G0/G1 accumulation were observed ( Figure 7B ). These findings demonstrate that AUY922-mediated depletion of ATR and CHK1 is not due to its effects on cell cycle status.
DISCUSSION
Although previous studies have highlighted CHK1 as a client protein of hsp90, we demonstrate here for the first time that ATR, which is upstream to CHK1 in the DDR signaling, also exhibits chaperone association with hsp90. This is supported by the observation that treatment with the hsp90 inhibitor AUY922 disrupts the binding of ATR to hsp90, promotes the shift in binding of ATR to hsp70 and induces polyubiquitylation of ATR, thereby directing ATR to proteasomal degradation. Consistent with this, while treatment with AUY922 decreased the half-life of ATR, co-treatment with bortezomib restored the levels of ATR. Furthermore, AUY922 treatment did not lower the mRNA levels of ATR, supporting the conclusion that the effect of AUY922 on ATR is largely post-transcriptional, resulting in attenuation of ATR levels. Our findings also show that the effect of AUY922 on ATR levels is dosedependent, as well as dependent on the exposure interval to AUY922. Similar effect on ATR levels was observed following exposure to the geldanamycin analogue 17-AAG. Importantly within 24 to 48 hours after AUY922 withdrawal, the levels of CHK1 and ATR were restored. This suggests that the biologic consequences of hsp90 inhibition by AUY922, resulting from the depletion of the client proteins would also abate over time. This finding has considerable implications for the clinical efficacy of hsp90 inhibitors such as AUY922 and 17-AAG (tanespimycin), since these agents are currently under clinical investigation (37, 38) . Our studies also clearly show that exposure to hsp90 inhibitor did not deplete ATM levels, suggesting that not all PIKK family members exhibit chaperone association with hsp90.
The mechanism underlying this difference between ATR versus ATM for chaperone dependence on hsp90 remains to be elucidated (17, 18) . Following this, total cell lysates were prepared and hsp90, hsp70 and ATR were immunoprecipitated.
Immunoblot analyses were performed for CHK1, ATR, hsp70 or hsp90α on the immunoprecipitates. 
